CLINICAL TRIAL: ANTITHYMOCYTE GLOBULIN ON PRESERVING BETA CELL FUNCTION IN NEW O

这个子项目是许多研究子项目中利用 资源由NIH/NCRR资助的中心拨款提供。子项目和 调查员(PI)可能从NIH的另一个来源获得了主要资金， 并因此可以在其他清晰的条目中表示。列出的机构是 该中心不一定是调查人员的机构。 实验药物胸腺球蛋白(Genzyme Corporation)是一种兔抗胸腺细胞球蛋白(ATG)，将在本研究中进行测试。胸腺球蛋白是一种抗体药物。抗体是一种特殊的蛋白质，旨在阻断或结合细胞表面的目标蛋白质。就胸腺球蛋白而言，它与你的白细胞(主要是T细胞)表面的蛋白质结合，要么将它们从你的身体中移除，要么改变它们的功能。研究人员希望剩余的T细胞或重新生长的新T细胞不会攻击β细胞。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The experimental drug Thymoglobulin (Genzyme Corporation), a rabbit antithymocyte globulin (ATG), will be tested in this research study. Thymoglobulin is an antibody medication. Antibodies are specialized proteins designed to block or bind to target proteins on the cell surface. In the case of Thymoglobulin it binds to proteins on the surface of your white blood cells (mainly T cells) and either removes them from your body or alters their function. The researchers are hoping that the remaining T cells or the new T cells that grow back will not attack the beta cells.